Can Tepezza Reverse Double Vision?

Thyroid Eye Disease, unfortunately, often causes visible changes such as eye bulging (proptosis), eyelid retraction, redness, swelling, and double vision (diplopia). Of these, double vision, medically known as diplopia, is one of the most frustrating and disabling symptoms of thyroid eye disease (TED) (2). It can make everyday activities such as reading, driving, using stairs, working on a computer, or even recognizing faces difficult. Indeed, many patients describe it as the symptom that most significantly impacts their independence and quality of life.

Tepezza® (teprotumumab) is a monoclonal antibody and targeted biologic therapy prescribed for the treatment of TED (3). With the introduction of Tepezza, many patients now grapple with an important question: can Tepezza reverse double vision?

The encouraging answer is that not only can it improve double vision, but in some patients, it can completely resolve it, particularly if treatment is initiated during the active course of the disease (3). However, as targeted therapy, it may not work equally well in every patient. Whether Tepezza successfully reverses diplopia depends on several factors, including the stage of TED, the extent of permanent muscle damage present, and how long symptoms have persisted.

Thyroid Eye Disease and Double Vision

To understand the mechanism behind Tepezza, it helps to first understand why double vision develops. In TED, the immune system mistakenly attacks the tissues behind the eye. This autoimmune inflammation causes enlargement of the extraocular muscles and expansion of the orbital fat.

Normally, both eyes move together in perfect synchrony so that the brain receives one clear image. In TED, swollen or stiff eye muscles disrupt proper eye coordination. As a result, the two eyes no longer focus in the same direction, causing the brain to receive two different images instead of one.

This condition is called binocular diplopia, meaning the double vision disappears when either eye is covered. Depending on whether one or multiple muscles are affected, patients may experience horizontal double vision, vertical double vision, double vision only when looking in certain directions, constant double vision throughout the day, and/or intermittent double vision that worsens with fatigue. The severity of these symptoms can range from mild inconvenience to a complete inability to drive or work.

Tepezza and its Mechanism of Action

Unlike conventional treatments like steroids, which are broad-spectrum immunosuppressants, Tepezza is a targeted biologic medication. Rather than broadly suppressing the immune system, it specifically blocks the insulin-like growth factor-1 receptor (IGF-1R) by binding to it and thereby disrupting a key signaling pathway involved in the autoimmune process that drives TED. Activation of the IGF-1 receptor contributes to the expansion of orbital fat, enlargement of the eye muscles, inflammation, and excess production of hyaluronic acid, all of which result in tissue remodeling that pushes the eye forward. Hence, by interrupting this pathway, Tepezza addresses the underlying disease process rather than simply reducing inflammation. This targeted mechanism explains why Tepezza helps improve diplopia, which was rarely achievable with steroids alone (4). Although the precise mechanism is still being studied, Tepezza treats an underlying source of TED rather than simply masking symptoms. As swelling decreases, the eye muscles can move more freely, allowing for normal eye alignment. This is why improvements in double vision often occur alongside reductions in eye bulging.

Resolution of Diplopia with Tepezza Treatment

While Tepezza does not produce consistent results across the board, clinical trials have shown that approximately 7 out of 10 patients experienced improvement in double vision during treatment, with more than half experiencing complete resolution by the end of the 24-week treatment period. This variation reflects differences in the underlying disease. This variation reflects differences in the underlying disease, including its severity (5).

In addition, the timing of treatment plays a major role. During the active inflammatory phase, swollen eye muscles are still relatively flexible, and damage is minimal. Reducing the accompanying inflammation during this stage allows muscles to heal, leading to improvement in eye alignment. Conversely, months or years of uncontrolled inflammation may cause the muscles to become permanently scarred and fibrotic. Once fibrosis develops, simply reducing inflammation is often insufficient to restore normal muscle movement. This may explain why some patients continue to experience diplopia even after successful reduction of swelling and eye bulging.

Another important factor in treatment effectiveness is whether or not the disease is considered active or chronic. Active TED is characterized by ongoing inflammation, progressive symptoms, and swollen muscles, which responds better to targeted therapy. Inactive (chronic) TED, on the other hand, shows little active inflammation and predominance of scar tissue, leading to permanent restriction of eye movement. Under these conditions, surgery may become the preferred treatment. Although Tepezza has demonstrated benefits even in patients with chronic disease, earlier treatment generally offers the greatest opportunity for reversing muscle dysfunction before permanent fibrosis develops.

How Soon Does Double Vision Improve After Tepezza Infusions

Given the nature of precision medicine and the condition of each patient, the timeline for improvement remains highly variable. Some patients begin noticing changes after only a few Tepezza infusions, while others improve gradually throughout the entire treatment course, which typically consists of 8 IV infusions spaced every 3 weeks over about 5 months. Because tissue remodeling takes time, improvements often continue throughout the treatment period, and patients should avoid judging effectiveness after only one or two infusions.

Return of Double Vision and Treatment Course

Unfortunately, diplopia could potentially return, and although many patients maintain lasting improvement, TED is an autoimmune condition that can occasionally relapse (6). The accompanying inflammation that follows autoimmune reactivation might cause double vision recurrence, and in some cases, persistent scar tissue may slowly alter eye alignment over time despite successful initial treatment. Therefore, regular follow-up with a TED specialist remains important even after completing therapy.

However, it is important to note that persistent diplopia after Tepezza does not necessarily mean that treatment has failed. Many patients experience dramatic reductions in other accompanying symptoms even if some double vision lingers. Residual diplopia is caused primarily by scarred eye muscles rather than active inflammation. In this scenario, additional options for resolution include prism glasses to realign images for certain patients, temporary patching of one eye for severe diplopia, and strabismus (eye muscle) surgery once the disease has stabilized. Eye muscle surgery is generally delayed until TED has become inactive and eye alignment has remained stable for several months. Surgery addresses structural changes that medication alone cannot completely reverse.

Tepezza offers something that previous medications could rarely achieve: the possibility of improving the underlying muscle abnormalities responsible for double vision. However, it should not be viewed as a guaranteed cure, and for many patients, the goals are to reduce inflammation, improve eye alignment, restore comfortable binocular vision, delay or avoid surgery, and improve quality of life. When battling severe flare-ups and impaired quality of life from TED, even partial improvement can significantly enhance daily activities such as reading, driving, and computer work.

The Bottom Line

For many patients with active TED, Tepezza for double vision represents one of the most effective medical treatments currently available. The best results are generally seen when treatment begins before chronic scarring develops in the eye muscles. Even when double vision is not completely eliminated, Tepezza infusion therapy often reduces inflammation, improves eye movement, and lessens symptom severity, making daily life easier.

Working with an experienced TED specialist allows Tepezza treatment to be tailored to your individual symptoms, disease activity, and long-term goals. If you want to learn more about Tepezza treatment for diplopia, schedule an appointment with Dr. Raymond Douglas.

References

1. Shah, S. S. & Patel, B. C. in StatPearls     (2025).
2. Johnson, B. T., Jameyfield, E. & Aakalu, V. K. Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. Curr Opin Neurol 34, 116-121 (2021). https://doi.org/10.1097/WCO.0000000000000894
3. <Tepezza FDA label.pdf>.   
4. Shabto, J. M., Stevens, S., Gregerson, C. & Kazim, M. Transformation of Thyroid Eye Disease Phenotype Following Teprotumumab Treatment. Ophthalmic Plast Reconstr Surg (2025). https://doi.org/10.1097/IOP.0000000000003110
5. Boutzios, G. et al. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study. Front Endocrinol (Lausanne) 14, 1186105 (2023). https://doi.org/10.3389/fendo.2023.1186105
6. Couch, S. M. Teprotumumab (Tepezza) for Thyroid Eye Disease. Mo Med 119, 36-41 (2022).